These inhibitors are primarily used for metastatic melanoma, non-small cell lung cancer, renal, and bladder cancers, and in CRC, they are often combined with PD-1/PD-L1 inhibitors (86, 89). The gene discussed is PDCD1; the disease is colorectal carcinoma.